<SEC-DOCUMENT>0000000000-21-012291.txt : 20220114
<SEC-HEADER>0000000000-21-012291.hdr.sgml : 20220114
<ACCEPTANCE-DATETIME>20211008143006
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-21-012291
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211008

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIONOMICS LIMITED/FI
		CENTRAL INDEX KEY:			0001191070
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3

	FILING VALUES:
		FORM TYPE:		UPLOAD

	BUSINESS ADDRESS:	
		STREET 1:		31 DALGLEISH STREET
		CITY:			THEBARTON
		STATE:			C3
		ZIP:			5031
		BUSINESS PHONE:		61 8 8354 6107

	MAIL ADDRESS:	
		STREET 1:		31 DALGLEISH STREET
		CITY:			THEBARTON
		STATE:			C3
		ZIP:			5031
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]#;VQO<E-P86-E+T1E=FEC94=R
M87DO4W5B='EP92]);6%G92](96EG:'0@,C0W+T9I;'1E<B]&;&%T941E8V]D
M92]4>7!E+UA/8FIE8W0O5VED=&@@,30R."],96YG=&@@,S8U+T)I='-097)#
M;VUP;VYE;G0@.#X^<W1R96%M"GB<[<&!     ,,@?^K=X 15 0
M
M
M
M
M
M
M
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M"U83J5T@@&P1%G"3H7!4FZX<NV,R$6PM:#;"!>>"GG!Q%%,ZAPK16+#E0+[
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MK:3?LM9=:]I%7O<^\N1EVL52)E3-B5RI732RP&YZQ7L;E9L\(;>$JFY"4DQ
MH^YKV*)=+-W#0>U"1&Y%]7'(YQZ+:_C5^=:=FV<$(3=#7]X=<F%0.7I%5H7M
M!T9W2,&-40'[-B9M^9#?C::(%\#9]88?=T?[BO1/80M9#U!^AI(.8RCO(')$
MH]JT(9EH071X:A=]JQI2N^CG>")?RO!%VY#]P7U@6,E-M(NX\YOW^$/B9SOQ
M8L!->\M,;[_N)O-Q*I@G-+XGS>3Y;],N3G+7:1?#U$C#'2=N/D-JYYP\V7I+
M-(N:+=K%TEGB;=$NYJ!L;S_?RG;M E*[^#@FX8(M;VF'ZQ1\Q.8'Q?!@>$TO
MT"Y^=9%4\ZNYY-6,GDV?9TOFMU"SV)^XV0Z%G1Z<7/JGQ_=H%\OAIWWR+NI-
M1YJF]EIQ7\/)H%Z[D?T)8<UZ^[T\W-#3:J)=\-4D1O2:!=1<N^AM^=88_MXQ
MQ.HCL?=PPPQ_356[F#B@G?S-WAWL9R;Z[4DCMZ;'=FH7(G([FO@,:V%VZESZ
M7.V"22^I1G;'J2FR,T^V?%?"U )_C7R \Q1E6,'*XNY@N4&9)D)%;'Q<![]7
M'%*HH?K#,K6^[_+$[8\AY;&XN#MF/Z&==0CH!XLZJ:YI4/I#3*9MG#O:$15B
M3]COPJ1:[4+^+)C$9S"6M%)(=Z>)7/!V3&&\D;F7%BL(@M+\.L;IY1<=S=LX
ME1J>"U7QQ)C'<&"BF R?G"PD:S$2<=9*:K?,9XQ-;6NOSQ*B,6?YX:2W:=Z6
MZ](?%$,^_/[VW8V!E=T% 2<S!/3)DR4^TO!R?)24V?MCI*,MW34\8G^@!F(T
M1:_.W=OGL.H\ZZ)P<9N3W1]^E;U<UI39'VZ\H=,3:O^^_,KX=<Q/L&G_Y*YN
M?D1Y=9I&SJ,-, D97KCFL3.YA9J6S&TFN=MKWK3=\>4%,Y#&+V#2VBT7]S+M
M8CGFY1Q>P6CDQELTGY-I)[#E@;\<[7_ZBYO?]L],S''[ZYC4WNOOBAH9+!L_
MOQ7QKCIYW>E)YHK[SX^X+9V9WF07/"'/^BWTO]ELY,F1L?X$YD>IEVD_THM$
M1"X M;QN83J13[/]T4HPG[=/QW0D&P_!P)1C-R,L2@(JQ+XLL3-_XJ]#5E9H
MWE\0$(/A \^(5!5^'[D?P5/Z)#G!N#L8DR.V()74Z0>G$,W#CG08LP(E9'^,
MH;'[G%XM#3#F(=K0+G+..9^<YU=J%_+'2==^?)\G$_6ZR_LYX.B]I<YT#"?X
MP 7G4BO97D]S1A,;C^;4+JADK?S)1DX.O=:\.9.WM,OG&^.:BS)L_'QI,"F\
MO8=/'O%D=]$#EYWO]J,TU!]+_^W)TSS9+?6:GBS<MW_[A5N[:L.SF'37!5=_
M_CM=VX4'(/.9+WH2$M[\9&,V-I6+>/US<DO_+.?\].I1)I?@W ?@EC:<==VO
M''0N>T*>>V<NQWAQUXQHVTLZ'161FX#E0[_]XYA.>E]RHS/MP2SM+(7_HT1I
M(#Q%KMG1+NH#D,+8<F>P"[2")B[9<K#+)3YVFC0,G4DO #$$VPSTEDS2FJTB
MZ!SZS\F @;NCF\GNZ&*?[9S/E#@N]=,YM*J/YO1Q\,%A"S%&'"Q$1$1$1$3D
M7P<W0SYC189A ,9=[X?D5NDHP48\#3=J%Z@?-;UIAHFH:3(:\383<NV.?B(8
M?F<-NV.<3#ZD() 6%]7ZHIIA##_7#W?'S*><;Z.9<"R"2-=8'-46#J/!H!$N
M[DJ(3BP \P1YT[%F@K@_ABI=CEE6:YUI+I*V?YA>X&ASX6TA(B(B(B(B\M>
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M1$1$KB?C-C1+]9I!-8GU^)I9PNOK:]9018]8[/]M"D8T[_[^OMJ3/#T]I?Y
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M2"6M9RS,,2T@#VF6G&@7I$\=I@Y95F)U(HP0&H*#LJ6&_5PZ[6(I\D54>'^
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M&H5^UGNNH#!NP.:A=5N'4P=7LKN&*5WJ0_?-E,.8H(2RO8#[QS$(VGI?4!3
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M941E8V]D92],96YG=&@@,C$P-3X^<W1R96%M"GB<U5A=C]LV%GV?7T'T91W
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MHD85&#DHL76_G<OS,%H-K.)$'[^EP6/?VL-)4>NY=C!$OYN=N&Q#C<:$*D]
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M?B;$9*+R<9YCH'7!8C97?*6K_(8_8,N+NQGA[60Q4W%'#,-N=H]![KB<.$Y
MV\\50W?J_A0Q=+%,]L30/BR&+K[C#(JA%I.8!$<G[]<BB**B!0[EZBSE:D%
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J96YD;V)J"B5I5&5X="TU+C0N-0IS=&%R='AR968*,S@Q-#4*)25%3T8*

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo





                             October 8, 2021

       Errol De Souza
       Executive Chairman
       Bionomics Limited/FI
       200 Greenhill Road
       Eastwood SA 5063
       Australia

                                                        Re: Bionomics Limited/
FI
                                                            Draft Registration
Statement on Form F-1
                                                            Submitted September
10, 2021
                                                            CIK No. 0001191070

       Dear Mr. Souza:

              We have reviewed your draft registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       DRS Form F-1 filed September 10, 2021

       Cover Page

   1.                                                   We note your statement
that the closing price of your ordinary shares on the Australian
                                                        Securities Exchange was
A$         per ordinary share, equivalent to a price of US$
                                                         per ADS. You may use
the most recent home market trading price, converted to U.S.
                                                        dollars at the most
recent exchange rate, assuming the U.S. IPO price will be largely based
                                                        on the home market
trading price. If you expect that the U.S. IPO price will not be
                                                        substantially the same
as the home market trading price, please disclose on the cover page
                                                        of the preliminary
prospectus a bona fide price range of the offered securities.
 Errol De Souza
FirstName
Bionomics LastNameErrol De Souza
           Limited/FI
Comapany
October    NameBionomics Limited/FI
        8, 2021
October
Page  2 8, 2021 Page 2
FirstName LastName
BNC210, page 2

2.       Please revise the summary to discuss briefly the federal and state
regulation of your
         combination of BNC210 and EMP-01 as a controlled substance. Please
also include any
         related risk in your bulleted risks listed on page 4.
3.       We note that you received Fast Track designation from the FDA for your
PTSD program.
         Please balance this with disclosure that such designation may not
result in a faster
         development process and does not assure approval by the FDA.
Our Portfolio, page 2

4.       We note the inclusion of undisclosed product candidates relating to
the treatment of pain
         and cognition in your pipeline table. Given the limited amount of
disclosure related to
         these programs, please explain why these programs are sufficiently
material to your
         business to warrant inclusion in your pipeline table. If they are
material, please expand
         your disclosure in your Business section to provide a more fulsome
discussion of these
         programs, including a description of preclinical studies or
development activities
         conducted. Alternatively, remove any programs that are not currently
material from your
         pipeline table on pages 2 and 106. Please also identify the two
product candidates that are
         in Phase 1 development under the Merck collaboration.
Legacy Oncology Programs, page 3

5.       Please quantify the amount of payments you have received to date under
the license
         agreement with Carina Biotech and the current stage of development of
BNC101 under
         the agreement.
Our Early-Stage CNS Assets, page 3

6.       We note your statement that your early stage programs are at a similar
stage to the stage at
         which the a7 receptor PAM program was licensed under the 2014 Merck
License
         Agreement. Please balance this disclosure with the fact that there is
no guarantee that
         these programs will ever be licensed out.
a7 Receptor PAM Program with Merck, page 3

7.       We note the statement that you are eligible to receive up to US$465
million in milestone
         payments for achievement of certain development and commercial
milestones.
         Please disclose that because Merck controls the clinical development
and worldwide
         commercialization of any products developed from the collaboration,
you cannot predict
         whether or when you might achieve any milestone payments under the
collaboration or
         estimate the full amount of such payments, and that you may never
receive any such
         payments. Additionally, please disclose you will not receive any
royalty payments from
         Merck as a result of the contingent value right to be issued for the
sole benefit of your
         existing shareholders. Please also explain the extent to which you
have access to
 Errol De Souza
FirstName
Bionomics LastNameErrol De Souza
           Limited/FI
Comapany
October    NameBionomics Limited/FI
        8, 2021
October
Page  3 8, 2021 Page 3
FirstName LastName
         information related to clinical trial results, serious adverse events
and ongoing
         communications with the FDA relating to these programs or the extent
to which Merck
         is required to provide you with this information.

Implications of Being an Emerging Growth Company and a Smaller Reporting
Company, page 5

8.       Please supplementally provide us with copies of all written
communications, as defined in
         Rule 405 under the Securities Act, that you, or anyone authorized to
do so on your behalf,
         present to potential investors in reliance on Section 5(d) of the
Securities Act, whether or
         not they retain copies of the communications.
Dilution, page 88

9.       Please revise your definition of net tangible book value to more
clearly explain your
         calculation of net tangible book value and per share information.
Licenses and Collaboration, page 94

10.      We note your disclosure here and on page 127 that Merck is required to
make tiered
         royalty payments on a product-by-product and country-by-country basis,
ranging from
         mid single-digit to low double-digit percentage royalty rates. Please
refine your disclosure
         to provide a more exact description of the high end of the range
(e.g., low teens) to ensure
         that you have described the royalty rate within a ten percentage point
range.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Results of Operations, page 98

11.      Please revise your discussion of other income on page 99 to quantify
the impact for each
         of the factors you cited for the change in the amounts between the
years ended June 30,
         2020 and June 30, 2021.
Business
Overview, page 106

12.      You make several assertions regarding the safety and efficacy of your
product candidates.
         Safety and efficacy determinations are solely within the authority of
the FDA (or
         applicable foreign regulator). You may present clinical trial end
points and objective data
         resulting from trials without concluding efficacy and you may state
that your product
         candidates have been well tolerated, if accurate. Please revise or
remove
         statements/inferences throughout your prospectus that your product
candidates are safe
         and/or effective. As a non-exhaustive list of illustrative examples
only, we note the
         following:

                On page 107, you state "BNC210 has...demonstrated anti-anxiety
and antidepressant
              effects..."
 Errol De Souza
Bionomics Limited/FI
October 8, 2021
Page 4
                On page 107, you refer to an extensive safety database.
                On page 107, you state "[W]e have observed three key
anxiety-reducing features
              associated with BNC210:
                o  statistically significant reductions in hyperactivity in the
amygdala, the region of
                   the brain responsible for emotional control, when exposed
                   to fear-inducing triggers;
                o  in a head-to-head study, showed a statistically significant
reduction in the
                   intensity of defensive behavior, while lorazepam, a widely
                   prescribed benzodiazepine did not; and
                o  a statistically significant reduction in the intensity and
total number of panic
                   symptoms as well as more rapid recovery from the panic state
                   relative to placebo
                On page 107, you state "a target blood exposure predicted to
show clinically
              meaningful benefit for patients suffering from PTSD."
                On page 109, you reference "favorable safety data" when
discussing BNC210.
                On page 114, you state BNC210 has the potential for "similar
clinical efficacy
              without many of the limiting side effects observed with
benzodiazepines, SSRIs and
              SNRIs."
                On page 125, you state "Representative molecules from each
series have been
              observed to reverse pharmacologically induced cognitive deficits
in mouse and rat
              models with equivalent efficacy to risperidone, an antipsychotic
drug used to treat
              schizophrenia, used as the positive control."
                On page 125, you state "Preclinical studies showed BNC101 was
able to target and
              reduce the frequency of cancer stem cells derived from primary
patient colorectal
              tumors both in vitro and in vivo."
Legacy Oncology Program, page 108

13.      We note that you have a license agreement with Carina Biotech and a
collaboration
         agreement with EmpathBio. Please provide the license and collaboration
agreements
         as exhibits, and please revise the descriptions of these agreements to
disclose:

              each parties' rights and obligations under the agreement;
              quantify all payment made to date;
              disclose separately the aggregate amount of all potential
development, regulatory and
            commercial milestone payments;
           disclose the amount of option fees for additional targets;
           quantify the royalty rate, or a range no greater than 10 percentage
points per tier;
           disclose when royalty provisions expire, if the expiration is based
on a number of
FirstName LastNameErrol
            years following De    Souza
                             commercialization,   disclose the number of years;
Comapany    NameBionomics
           disclose              Limited/FI
                     the expiration date; and
October    8, 2021
            describe any
                  Page 4 termination provisions.
FirstName LastName
 Errol De Souza
FirstName
Bionomics LastNameErrol De Souza
           Limited/FI
Comapany
October    NameBionomics Limited/FI
        8, 2021
October
Page  5 8, 2021 Page 5
FirstName LastName
Our Strategy, page 109

14.      We note your disclosure here and throughout your prospectus regarding
your goal of
         developing and commercializing "novel, first-in-class" treatments.
Please remove
         references to "first-in-class" as this statement implies an
expectation of regulatory
         approval and is inappropriate given the length of time and uncertainty
with respect to
         securing marketing approval. If your intention is to convey your
belief that your platform
         or your programs utilize a novel technology or approach, you may
discuss how your
         technology differs from technology used by competitors or that you are
not aware of
         competing products that are further along in the development process.
Statements such as
         these should be accompanied by cautionary language that the statements
are not intended
         to give any indication that your technology or any potential product
candidates have been
         proven effective or will receive regulatory approval.
15.      We note your disclosure here and in the Summary that your strategy is
to
         "rapidly progress" clinical development for your BNC210 product.
Please revise these
         statements and any similar disclosure to remove any implication that
you will be
         successful in commercializing your product candidates in a rapid or
accelerated manner as
         such statements are speculative.
Potential Advantages of BNC210 for the Treatment of Anxiety and
Stressor-Related Disorders,
page 114

16.      Please remove the table on page 115 regarding BNC210 vs. current
therapies. The
         table implies an expectation of regulatory approval and is
inappropriate given the early
         stage of development of BNC210.
Clinical Development of BNC210, page 115

17.      Please revise your graphics throughout pages 119-122 so that they are
large enough to be
         legible for investors.
18.      Please provide p-values for the results of your trials or explain why
you are unable to
         provide such values. At first use, please provide a brief explanation
of the disclosed p-
         value and how it is used to measure statistical significance.
Intellectual Property, page 128

19.      We note your statements that you have patented 1) two series of small
molecule inhibitors
         with functional selectivity for Nav1.7 and Nav1.8 voltage gated sodium
channels for the
         treatment of chronic pain and 2) two series of small molecule
Kv3.1/3.2 potassium
         channel activators for the potential treatment of cognitive deficits
and negative symptoms
         in schizophrenia and for the treatment of autism spectrum disorders.
Please expand your
         Intellectual Property section to include descriptions of these
patents.
 Errol De Souza
FirstName
Bionomics LastNameErrol De Souza
           Limited/FI
Comapany
October    NameBionomics Limited/FI
        8, 2021
October
Page  6 8, 2021 Page 6
FirstName LastName
Principal Shareholders, page 162

20.      Please identify the natural person or persons who directly or
indirectly exercise sole or
         shared voting and/or dispositive power with respect to the common
stock held by BVF
         Partners L.P. and Apeiron Investment Group Ltd.
Consolidated Financial Statements , page F-3

21.      You disclose in Note 2(ii) that all amounts in the financial
statements are presented in
         Australian dollars. Please state the currency on the face of the
financial statements as you
         have done elsewhere in the filing and as required under Rule 3-20 of
Regulation S-X.
Notes to the Financial Statements
Note 2: Summary of Significant Accounting Policies
(iii) Application of New and Revised Accounting Standards , page F-9

22.      You stated on page 6 that you are an Emerging Growth Company ("EGC")
and elected to
         take advantage of an extended transition period for complying with new
or revised
         accounting standard. We further note you adopted all the new and
revised Standards and
         Interpretations issued by the IASB and effective for an accounting
period that begins on or
         after July 2020. However, the EGC accounting deferral is not
applicable to IFRS filers.
         Refer to the cover page of Form F-1, and please revise accordingly.
       You may contact Christie Wong at 202-551-3684 or Kevin Vaughn at
202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jordan Nimitz at 202-551-6001 or Christopher Edwards at 202-551-6761
with any other
questions.



                                                               Sincerely,

                                                               Division of
Corporation Finance
                                                               Office of Life
Sciences
cc:      Nathan Ajiashvili, Esq.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
